TREE NEWS reports: Summit, partner of Akeso, received a complete response letter from the US FDA for its BLA of ivonescimab combined with chemotherapy in TKI-treated non-small cell lung cancer, UBS said in a research note. UBS called the development mildly negative and a sentiment overhang, citing failure to reach statistical significance on the overall survival endpoint. It estimated peak sales for the indication at RMB550 million, just 1% of ivonescimab’s total overseas sales, and maintained a Buy rating and HK$149 target price on Akeso.
UBS: FDA Complete Response Letter for Akeso Partner’s Ivonescimab BLA Mildly Negative
UBS's framing is the real story here: the setback is being sized down to a rounding error against ivonescimab's broader overseas opportunity, which tells you where the bank sees the value concentrated. The OS miss matters most for the specific TKI-treated lung indication rather than the asset as a whole, so the read-across to Akeso's wider pipeline is the question worth tracking. Whether the CRL proves a contained, single-indication issue or signals deeper regulatory scrutiny of the survival data is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.